Načítá se...
Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis
Ruxolitinib is a recommended second-line treatment for the prevention of thrombosis in patients with polycythemia vera who become resistant or intolerant to hydroxyurea; however, evidence regarding its efficacy in terms of thrombosis reduction is uncertain. We searched Medline, Embase, and archives...
Uloženo v:
| Vydáno v: | Blood Adv |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society of Hematology
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6988397/ https://ncbi.nlm.nih.gov/pubmed/31985808 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001158 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|